Revue: | Brazilian Journal of Pharmaceutical Sciences |
Base de datos: | PERIÓDICA |
Número de sistema: | 000452142 |
ISSN: | 1984-8250 |
Autores: | Rasouli, Azadeh1 Aliebrahimi, Shima2 Montazeri, Vahideh1 Ghahremani, Mohammad Hossein1 Ostad, Seyed Nasser1 |
Instituciones: | 1Tehran University of Medical Sciences, Faculty of Pharmacy, Teherán. Irán 2Virtual University of Medical Sciences, Department of Medical Education, Teherán. Irán |
Año: | 2022 |
Volumen: | 58 |
País: | Brasil |
Idioma: | Inglés |
Tipo de documento: | Artículo |
Enfoque: | Experimental, aplicado |
Resumen en inglés | Hypoxia-inducible factors (HIFs) and cancer stem cells (CSCs) are two challenging causes of radiotherapy and chemotherapy resistance, leading to most cases of failure and recurrence in breast cancer therapy. This study was conducted to investigated the inhibitory effect of combination therapy with doxorubicin (an anthracycline) and FM19G11 (an HIF inhibitor) on MCF-7 cells and their CSC-like cells (CSC-LCs). MCF-7 CSC-LCs with a CD44+/CD24- phenotype were sorted and characterized by flow cytometry. A combination of doxorubicin and FM19G11 caused more cytotoxic effects on MCF-7 and CSC-LCs compared to doxorubicin monotherapy. The largest synergistic effect was observed in CSC-LCs under hypoxic conditions; however, MCF-7 cells showed no synergism in normoxic conditions. The administration of doxorubicin and FM19G11 induced late apoptotic and necrotic cell death in MCF-7 and CSC-LCs. Additionally, G2 phase arrest was observed in both cells. Our results demonstrated that co-administration of FM19G11 and doxorubicin had a synergistic effect in hypoxia and improved drug resistance in breast cancer stem cells |
Disciplinas: | Medicina |
Palabras clave: | Oncología, Farmacología, Doxorrubicina, Factor inductor de hipoxia, Indice de combinación, Citotoxicidad, Células troncales cancerosas |
Keyword: | Oncology, Pharmacology, Doxorubicin, Hypoxia-inducible factor, Combination index, Cytotoxicity, Cancer stem cells |
Texte intégral: | Texto completo (Ver HTML) Texto completo (Ver PDF) |